Enliven Therapeutics Inc. (ELVN) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Enliven Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$44.78
+2.49% today
Market cap
$3.2B
Overall quality
44/100
Kronos AI 30-day
+3.2%
5 of 8 simulated paths end higher
Enliven Therapeutics Inc. (ELVN) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $3.2B. It trades at $44.78, up 2.49% today. Its overall quality score is 44 out of 100, ranked against the whole US market. 14 analysts' average target of $74.33 implies +66.0% from today's price. Kronos AI's 30-day forecast is +3.2% (5 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $74.33 |
| Low – high | $68.00 – $82.00 |
| Analysts | 14 |
| Upside to average | +66.0% |
Kronos AI 30-day forecast
| Expected close | $45.09 (+3.2%) |
| Likely range | −2.6% … +22.9% |
| As of | 2026-10-27 |
5 of 8 simulated paths end higher.
Quality scores
| Profitability | 44 |
| Solvency | 57 |
| Growth | 31 |
| Overall | 44 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.